Basic Information
| LncRNA/CircRNA Name | MEG3 |
| Synonyms | NA |
| Region | GRCh38_14:100779410-100861031 |
| Ensemble | ENSG00000214548 |
| Refseq | NR_002766 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR, Western blot, Luciferase reporter assay, RIP, etc. |
| Sample | prostate cancer tissues, prostate cancer cell lines PC-3, DU145 and VCaP, 22RV1 |
| Expression Pattern | down-regulated |
| Function Description | LncRNA MEG3 was a down-regulated lncRNA in prostate cancer tissues and cells and could inhibit the expression of miR-9-5p, whereas miR- 9-5p down-regulated QKI-5 expression. Overexpressed MEG3 and QKI-5 could decrease the abilities of proliferation, migration and invasion in prostate cancer cells effectively and increased the apoptosis rate. On the contrary, miR-9-5p mimics presented an opposite tendency in prostate cancer cells. Furthermore, MEG3 inhibited tumour growth and up-regulated expression of QKI-5 in vivo. LncRNA MEG3 was a down-regulated lncRNA in prostate cancer and impacted the abilities of cell proliferation, migration and invasion, and cell apoptosis rate, this regulation relied on regulating miR-9-5p and its targeting gene QKI-5. |
| Pubmed ID | 30565858 |
| Year | 2019 |
| Title | LncRNA MEG3 inhibits the progression of prostate cancer by modulating miR-9-5p/QKI-5 axis |
External Links
| Links for MEG3 | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |